Table 3 Guideline comparison summary table

Dermatology

N = 2^a

N = 16

N = 16

N = 1

N = 15

Recommended: 1 (50%)

Not recommended for routine use: 1 (50%)

Do: 4 (25%)

Do not do: 0

Do not know: 12 (75%)

Indicated conditions: 4(25%)

Possibly indicated conditions: 12(75%)

Approved/Recommended: 1 (100%)

Not recommended: 0

Recommended: 2 (13%)

Possible option: 7 (47%)

Not recommended: 4 (27%)

Insufficient data: 2 (13%)

Hematology

N = 14

N = 22

N = 16

N = 5

N = 23

Recommended: 5 (36%)

Not recommended for routine use: 9 (64%)

Do: 12 (55%)

Do not do: 3 (14%)

Do not know: 7 (32%)

Indicated conditions: 9 (56%)

Possibly indicated conditions: 7 (44%)

Approved/Recommended: 4 (80%)

Not recommended: 1 (20%)

Recommended: 5 (22%)

Possible option: 9 (39%)

Not recommended: 7 (30%)

Insufficient data: 2 (9%)

Immunology

N = 2^a

N = 2

N = 5

N = 2

N = 42

Recommended: 2 (100%)

Not recommended for routine use: 0

Do: 2 (100%)

Do not do: 0

Do not know: 0

Indicated conditions: 4 (80%)

Possibly indicated conditions: 1 (20%)

Approved/Recommended: 2 (100%)

Not recommended: 0

Recommended: 11 (26%)

Possible option: 11 (26%)

Not recommended: 11 (26%)

Insufficient data: 9 (21%)

Infectious Disease​

N = 2

N = 11

N = 4

N = 3

N = 13

Recommended: 2 (100%)

Not recommended for routine use: 0

Do: 4 (36%)

Do not do: 6 (55%)

Do not know: 1 (9%)

Indicated conditions: 2 (50%)

Possibly indicated conditions: 2 (50%)

Approved/Recommended: 3 (100%)

Not recommended: 0

Recommended: 0

Possible option: 3 (23%)

Not recommended: 7 (54%)

Insufficient data: 3 (23%)

Transplant Medicine​

N = 4

N = 21

N = 3

N = 0

N = 11

Recommended: 4 (100%)

Not recommended for routine use: 0

Do: 6 (28%)

Do not do: 9 (43%)

Do not know: 6 (28%)

Indicated conditions: 1 (33%)

Possibly indicated conditions: 2 (67%)

Recommended: 0

Possible option: 5 (45%)

Not recommended: 2 (18%)

Insufficient data: 4 (36%)

Neurology

N = 10

N = 49

N = 19

N = 12

N = 27

Recommended: 4 (40%)

Not recommended for routine use: 6 (60%)

Do: 15 (31%)

Do not do: 16 (32%)

Do not know: 18 (37%)

Indicated conditions: 6 (32%)

Possibly indicated conditions: 13 (68%)

Approved/Recommended: 4 (33%)

Not recommended: 8 (67%)

Recommended: 4 (15%)

Possible option: 9 (33%)

Not recommended: 9 (33%)

Insufficient data: 5 (19%)

Rheumatology

N = 3

N = 22

N = 11

N = 2

N = 34

Recommended: 3 (100%)

Not recommended for routine use: 0

Do: 8 (36%)

Do not do: 4 (19%)

Do not know: 10 (45%)

Indicated conditions: 4 (36%)

Possibly indicated conditions: 7 (64%)

Approved/Recommended: 2 (100%)

Not recommended: 0

Recommended: 1 (3%)

Possible option: 12 (35%)

Not recommended: 11 (32%)

Insufficient data: 10 (29%)

Total

N = 37

N = 143

N = 74

N = 25

N = 165

Level 1: Total recommended: 21 (57%)

Level 2: Total not recommended for routine use: 16 (43%)

Level 1: Total do: 51 (36%)

Level 3: Total do not do: 38 (26%)

Level 4: Total do not know: 54 (38%)

Level 1: Total indicated conditions: 30 (41%)

Level 2: Total possibly indicated conditions: 44 (59%)

Level 1: Total Approved/recommended: 16 (64%)

Level 3: Total not recommended: 9 (36%)

Level 1: Total recommended: 23 (14%)

Level 2: Total possible option: 56 (34%)

Level 3: Total not recommended: 51 (31%)

Level 4: Total insufficient data: 35 (21%)